A1 China's most significant achievement has been the profound development in people's health and livelihoods. China is becoming a leader in global healthcare and the government is reforming pharmaceutical innovation to allow patients greater access to cutting-edge treatments.

Johnson & Johnson entered the Chinese mainland in 1985 with the opening of Xi'an Janssen - one of the first joint venture pharmaceutical companies in China. We now have 16 legal entities in China, eight production bases across all our three business sectors - pharmaceutics, medical devices and consumer with more than 10,000 people in 90 cities.

A2 As a leading healthcare company, we are delighted to see the Chinese government promote high-quality growth. Driving high-quality growth is also the strategy that Johnson & Johnson has fostered in China. We are continuously introducing innovative products and technologies as well as strengthening our own R&D capabilities in China.

A3 The legislation on foreign investment demonstrates China's determination to expand its opening to the outside world and create a more open, fair and transparent investment environment. We are glad to see that the law clearly states that multinational corporations will be treated equally and we hope that mandatory standards will be reduced to encourage product innovation. The law will allow us to protect our latest treatments, and we warmly welcome the government's efforts to open the economy and give Chinese patients new ways of receiving vital care.

A4 We strongly support the government's "Healthy China 2030" plan to deliver accessible and comprehensive care and are continuing to introduce the most advanced treatments as well as grow the healthcare ecosystem to reinforce these aims.

In 2018, all our business sectors yielded extraordinary results in China. These won't be possible without the favorable government policies to speed up the approval process for drugs and medical devices, the fast-changing consumption upgrade landscape, and most importantly, our dedication and commitment to addressing the unmet needs of our patients and consumers in China.

A5 The government's strong efforts to enhance efficiency in the healthcare sector over the last two years have been transformative. We applaud the numerous positive steps to exclude cancer medicines from tariffs; reduce the price of cancer treatments; incorporate innovative imported drugs, especially much-needed cancer treatments, into the catalog of medical insurance reimbursement; and accelerate national reimbursement drug list approval for innovative therapies.